Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New heartburn test could replace uncomfortable procedures

NCT ID NCT07437768

Diagnosis Sponsor: Fu Jen Catholic University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a 4-week course of vonoprazan, a stronger acid blocker, can help identify which patients with persistent heartburn actually have acid reflux. About 100 adults with symptoms that don't improve on standard treatment will take the drug and complete symptom questionnaires. The goal is to see if response to vonoprazan can replace invasive monitoring tests, making diagnosis easier and cheaper.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
vonoprazan (VOCINTI®)
What this could lead to
If successful, this could offer a simpler, non-invasive way to diagnose acid reflux in patients who don't respond to standard heartburn drugs, reducing the need for uncomfortable tests.
What could go wrong
This is a small, early-stage study with only 100 participants. The results may not apply to everyone, and the test might not clearly distinguish between acid-related and non-acid-related symptoms.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2025

Expected to finish

Oct 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

20 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients aged between 20 and 75 years. * Outpatients at Fu Jen Catholic University Hospital who had undergone esophagogastroduodenoscopy (EGD) within the past year. * Presence of persistent GERD symptoms, including acid regurgitation, heartburn, chest pain, globus sensation, or chronic cough. PPI-refractory GERD, defined as persistent symptoms despite receiving at least 8 weeks of standard-dose proton pump inhibitor (PPI) therapy (GerdQ \> = 8). * Scheduled to undergo high-resolution manometry (HRM) and 24-hour esophageal pH-impedance monitoring. * Patients with a history of any grade of erosive esophagitis confirmed by gastroscopy. Exclusion Criteria: * major esophageal motility disorders * history of upper gastrointestinal surgery * malignant tumors * liver cirrhosis. * esophageal strictures * esophageal varices * gastrointestinal obstruction * significant acute GI bleeding * LA Grade B, C, or D erosive esophagitis, * esophageal peptic stricture * biopsy-proven Barrett's esophagus * severe renal impairment (CrCl \< 30 mL/min) * long-term dialysis, pregnancy * hypersensitivity to vonoprazan or its excipients. * patients currently taking atazanavir sulfate or rilpivirine hydrochloride, * dependent on tube feeding * unable to cooperate due to impaired consciousness

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NERD are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

gastroesophageal reflux disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NERD PCAB Refractory GERD

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Fu Jen Catholic University Hospital

    New Taipei City, Taiwan, 24352, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.